Axion’s MEA systems can model complex brain activity and heartbeats in a dish. As a result, toxicity and efficacy can be assessed earlier in the drug development process, and with greater sensitivity and accuracy. These comprehensive system-level evaluations provide an in vitro solution to reducing animal testing, a key objective of the Tox21 and REACH initiatives.
Axion’s MEA systems provide a label-free in vitro platform for direct measurement of electrical activity in neurons and cardiomyocytes, while the efficiency and convenience of Axion’s standard MEA plates facilitate use for screening-level applications. The large number of electrodes per well reveals detailed information about systems-level signal propogation.
MEA Workshop, May 15th – Philadelphia, PA
Axion and Cyprotex are teaming up to host the North American MEA Workshop, Friday May 15th in the Philadelphia area. Included in the event are presentations from industry leaders on the use of the Maestro system in their research, hands-on demonstrations of the Maestro system, and a hot buffet lunch.
Click here for additional information. To register please visit www.cyprotex.com/mea-workshop or use this link.
Axion’s Maestro highlighted in Charles River Labs’ cardiac safety testing portfolio
Visit Charles River Labs’ recent blog post detailing the proposed CiPA initiative. In the spotlight: incorporation of an iPSC cardiomyocyte assay run on the Maestro platform.
View the post